NCT05442008View on ClinicalTrials.gov

Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment

CompletedOBSERVATIONAL
Enrollment

53

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2021

Conditions
Migraine
Interventions
DRUG

Erenumab 70/140 mg s.c.

Monoclonal antibody directed against the receptor of the Calcitonin Gene Related Peptide (CGRP)

Trial Locations (1)

27100

Headache Science & Neurorehabilitation Center, Pavia

All Listed Sponsors
lead

"IRCCS National Neurological Institute C. Mondino Foundation"

OTHER

NCT05442008 - Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment | Biotech Hunter | Biotech Hunter